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A B S T R A C T
Background
This is an updated version of the original review that was first published in the Cochrane Database of Systematic Reviews 2008, Issue
4. Laparoscopy has become an increasingly common approach to surgical staging of apparent early-stage ovarian tumours. This review
was undertaken to assess the available evidence on the benefits and risks of laparoscopy compared with laparotomy for the management
of International Federation of Gynaecology and Obstetrics (FIGO) stage I ovarian cancer.
Objectives
To evaluate the benefits and risks of laparoscopy compared with laparotomy for the surgical treatment of FIGO stage I ovarian cancer
(stages Ia, Ib and Ic).
Search methods
For the original review, we searched the Cochrane Gynaecological Cancer Group Trials (CGCRG) Register, Cochrane Central Register
of Controlled Trials (CENTRAL 2007, Issue 2), MEDLINE, EMBASE, LILACS, Biological Abstracts and CancerLit from 1 January
1990 to 30 November 2007. We also handsearched relevant journals, reference lists of identified studies and conference abstracts. For
this updated review, we extended the CGCRG Specialised Register, CENTRAL, MEDLINE, EMBASE and LILACS searches to 6
December 2011.
Selection criteria
Randomised controlled trials (RCTs), quasi-RCTs and prospective cohort studies comparing laparoscopic staging with open surgery
(laparotomy) in women with stage I ovarian cancer according to FIGO.
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Data collection and analysis
There were no studies to include, therefore we tabulated data from non-randomised studies (NRS) for discussion.
Main results
We performed no meta-analyses.
Authors’ conclusions
This review has found no good-quality evidence to help quantify the risks and benefits of laparoscopy for the management of early-
stage ovarian cancer as routine clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Laparoscopy versus laparotomy (open surgery) for early-stage ovarian cancer
Stage I ovarian cancer is diagnosed when the tumour is confined to one or both ovaries, without spread to lymph nodes or other parts
of the body. Approximately 25% of women with ovarian cancer will be diagnosed at an early stage, thus the diagnosis often occurs due
to an accidental finding. The intention of surgical staging is to establish a diagnosis, to assess the extent of the cancer and to remove as
much tumour as possible. The latter is particularly important as women with ovarian cancer survive for longer when all visible tumour
has been removed.
We conducted this review in an attempt to clarify whether laparoscopy (keyhole surgery) is as safe and effective as laparotomy (open
surgery) for early-stage ovarian cancer. We intended to include only high-quality studies that compared the two types of surgery.
We wanted to know whether women having laparoscopy survived as long as those having open surgery and whether there were differences
in the time it took for the cancer to get worse. We were also interested to see how these different surgeries compared with regard to
blood loss and other complications.
Unfortunately, we were unable to find any high-quality randomised trials comparing these approaches. Further research is needed.
B A C K G R O U N D
Description of the condition
This is an updated version of the original review that was first
published in the Cochrane Database of Systematic Reviews 2008,
Issue 4.
Ovarian cancer is the eighth most common cancer in women
worldwide (Jemel 2011). A woman’s risk of developing ovarian
cancer before the age of 75 ranges from 0.5% in developing coun-
tries to 1% in developed countries (GLOBOCAN 2008; Jemel
2011). Just over a third of women with ovarian cancer are alive five
years after diagnosis (EUROCARE 2003), largely because most
women with ovarian cancer are diagnosed when the cancer is al-
ready at an advanced stage (Jemal 2008). International Federa-
tion of Gynaecology and Obstetrics (FIGO) stage I ovarian cancer
(limited to the ovaries) is diagnosed in approximately 20% to 33%
of women with ovarian cancer in developed countries (Maringe
2012) and diagnosis is usually made by accidental discovery at
sonography, computerised tomography (CT scanning) or during
laparoscopy. The incidence of accidental discovery of ovarian can-
cer at laparoscopy has been estimated to range from 0.65% (Wenzl
1996) to 0.9% (Muzii 2005) of premenopausal women and 3%
of postmenopausal women who undergo the procedure for an ad-
nexal mass (Muzii 2005), but may be higher depending on the
selection criteria applied.
Most cancers of the ovary are epithelial (90%) with histological
subtypes including serous (35%), endometrioid (10%), border-
line (16%), mucinous (8%), clear cell (4%), undifferentiated and
mixed epithelial (Kosary 2007). In general, the prognosis of ovar-
ian tumours depends on the FIGO stage, tumour grade, histolog-
ical subtype, age and the volume of residual disease after surgery
(Benedet 2000), however for stage I tumours the most important
prognostic indicators are considered to be the degree of differ-
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entiation (grade) and the occurrence of tumour rupture (Vergote
2001).
The standard management of women with ovarian cancer is com-
prehensive surgical staging by laparotomy, a midline abdominal
incision that allows exposure of the entire abdomen. Comprehen-
sive surgical staging includes a total hysterectomy, bilateral salp-
ingo-oophorectomy, removal of all obvious sites of tumour, aspi-
ration of cytological washings or ascites, omentectomy, retroperi-
toneal (pelvic and para-aortic) lymph node dissection or sampling
and biopsy of all suspicious-looking areas including mesentery,
liver and diaphragm (Benedet 2000; Schorge 2012). Systematic
retroperitoneal lymph node dissection (RLND) may improve sur-
vival in stage I ovarian cancer by detecting microscopic disease
(Chan 2007) and is considered a standard procedure in some cen-
tres (Schorge 2012), however the UK National Institute for Clin-
ical Excellence (NICE) guidelines currently do not recommend
RLND in stage I disease (NICE 2011).
A meta-analysis of four randomised controlled trials (RCTs) of ad-
juvant platinum-based chemotherapy, which included data from
the International Collaborative Ovarian Neoplasm 1 (ICON1)
trial (Trimbos 2003) and the Adjuvant Chemotherapy in Ovar-
ian Neoplasm (ACTION) trial (Trimbos 2004), found that ad-
juvant chemotherapy significantly improved overall survival (OS)
and progression-free survival (PFS) in women with early ovarian
cancer (Winter-Roach 2012). However, it was considered not to
be necessary in women with comprehensively staged, stage Ia or 1b
grade 1 to 2 tumours, as subgroup analyses suggested that women
who were optimally staged were unlikely to benefit from adjuvant
chemotherapy. Hence, comprehensive surgical staging has an im-
portant impact on the subsequent management of women with
early ovarian cancer, with adjuvant chemotherapy indicated when
staging is considered to be inadequate (Elit 2004; Winter-Roach
2012).
Description of the intervention
The intention of surgical staging is to establish a diagnosis, to
assess the extent of the disease and to remove as much gross tu-
mour as possible (Schorge 2012). Surgical staging of ovarian can-
cer by laparoscopy is the same intra-abdominal procedure as that
performed by laparotomy except that it involves two or more,
much smaller, abdominal incisions, through which laparoscopic
instruments are then inserted. Specimen retrieval bags are used
to prevent spillage and possible seeding of cyst contents and to
avoid contact with incision (port) sites. Cysts may be aspirated
within the retrieval bag, or morcellated if solid, to facilitate extrac-
tion through the port sites (Ghezzi 2007). Larger specimens, like
omentum, may be extracted through the vagina with the uterus
after hysterectomy (Lee 2011; Park 2008a).
How the intervention might work
Several recent non-randomised studies (NRSs) in early ovarian
cancer have reported that laparoscopic surgical staging is a safe
and technically feasible procedure (Colomer 2008; Ghezzi 2009;
Nezhat 2009; Park 2008b; Park 2010). The possible advantages
of laparoscopy include smaller incisions, less blood loss, faster re-
covery, shorter hospital stay, fewer complications, less postopera-
tive infection and a better visualisation of the tumour inside the
abdomen as the laparoscopy image can be magnified (Gad 2011;
Ghezzi 2007; Lee 2011). In addition, the shorter recovery pe-
riod following laparoscopy means that chemotherapy can be com-
menced sooner compared with laparotomy (Ghezzi 2007; Nezhat
2009), potentially resulting in a favourable effect on survival.
However, laparoscopy has been associated with a higher rate of in-
traoperative cyst rupture for apparently benign (Muzii 2005) and
borderline tumours (Fauvet 2005), which may result in upstaging
of the unexpected ovarian cancer from stage Ia or 1b to Ic (Muzii
2005). It has been argued that some aspects of comprehensive sur-
gical staging, particularly RLND, may be technically difficult to
achieve via laparoscopy and, therefore, that laparoscopy should be
restricted to women with pre-operative evidence of benign con-
ditions only (Vergote 2004). Other disadvantages of laparoscopy
may include longer operating times and the possibility of port-
site metastases, although the risk of the latter in early disease is
considered to be low (Schorge 2012). Furthermore, to facilitate
laparoscopy, CO is commonly used for pneumoperitoneum and
has been shown to lower the peritoneal pH (Bergstrom 2008;
Kuntz 2000) which may activate enzymes that increase tumour
cell mitosis and growth factor production. In addition, mechan-
ical damage to the mesothelium may occur with prolonged la-
paroscopic surgery, thereby increasing the risk of metastases in the
abdominal cavity (Greene 1995; Volz 1999).
Why it is important to do this review
Laparoscopic surgical staging of stage I ovarian cancer remains
controversial as it is unclear how the risks and benefits of this pro-
cedure compare with the conventional open approach by laparo-
tomy. An earlier version of this systematic review, published in
2008, found insufficient evidence to evaluate laparoscopy for the
management of early ovarian cancer as routine clinical practice.
We continue to update this review with the aim of clarifying and
consolidating the available evidence regarding this alternative sur-
gical approach.
O B J E C T I V E S
To evaluate the benefits and harms of laparoscopy in the surgical
treatment of FIGO stage I ovarian cancer (stages Ia, Ib and Ic)
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when compared with laparotomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs. We also considered prospective cohort
studies where the results had been adjusted for the baseline case
mix using multivariate analyses, and excluded those with historical
(non-concurrent) controls.
Types of participants
Women with stage I ovarian cancer defined by FIGO as follows.
• Stage Ia: unilateral tumours
• Stage Ib: bilateral tumours
• Stage Ic: identified tumour spillage, tumour capsular
penetration, positive peritoneal cytology
Types of interventions
Surgical staging via laparoscopy (experimental group) versus la-
parotomy (control group) for stage I ovarian cancer.
Types of outcome measures
Primary outcomes
1. Overall survival (OS)
2. Progression free survival (PFS)
Secondary outcomes
1. Operating time
2. Intraoperative tumour rupture
3. Pelvic and para-aortic lymph node yield
4. Size of omental specimen
5. Estimated blood loss and the need for blood transfusion
6. Comprehensive staging achieved by the allocated procedure
(conversion to laparotomy)
7. Surgical complications (immediate and delayed) including:
injuries to the bladder, ureter, blood vessels, nerves, small bowel
and colon; febrile morbidity; intestinal obstruction; haematomas
and infections
8. Length of hospital stay
9. Time to adjuvant chemotherapy
10. Systemic complications
11. Abdominal wall recurrence: laparoscopy (port sites) and
laparotomy (midline incision).
12. Quality of life
Search methods for identification of studies
Electronic searches
We conducted searches to identify all published and unpublished
RCTs and NRSs that compared laparoscopy and laparotomy for
stage I ovarian cancer. The search strategies identified studies in
all languages and, when necessary, we translated non-English lan-
guage papers so that they could be fully assessed for potential in-
clusion in the review.
We searched the Cochrane Gynaecological Cancer Review Group
(CGCRG) Trials Register, Cochrane Central Register of Con-
trolled Trials (CENTRAL 2007, Issue 2), MEDLINE (January
1990 to November 2007), EMBASE (1990 to November 2007),
LILACS (1990 to November 2007), Biological Abstracts (1990 to
November 2007) and CancerLit (1990 to November 2007). For
this updated version of the review, we extended these searches to 6
December 2011. (See Appendix 1, Appendix 2, Appendix 3 and
Appendix 4 for the search strategies).
Searching other resources
We handsearched the citation lists of relevant publications and in-
cluded studies, and contacted experts in the field to identify further
trials. For the original review we also handsearched the following
conferences and publications: Gynecologic Oncology, International
Journal of Gynaecological Cancer, British Journal of Cancer, British
Cancer Research Meeting, Annual Meetings of the International
Gynaecologic Cancer Society, Annual Meetings of the American
Society of Gynecologic Oncologists, Annual Meetings of the Eu-
ropean Society of Medical Oncology (ESMO), and Annual Meet-
ings of the American Society of Clinical Oncology (ASCO).
Data collection and analysis
Selection of studies
Two review authors sifted the searches and identified potentially
eligible studies. All authors assessed the methodology of these po-
tentially eligible studies according to the specific inclusion crite-
ria. Review authors were not blind to the authors, institutions or
journals of potentially relevant studies.
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Data extraction and management
No studies fulfilled the inclusion criteria for this review. For future
versions of this review, two authors will independently extract data
from included trials to a pre-designed data collection sheet that
includes the following information:
• Study methodology: description of randomisation, blinding,
number of study centres, study duration, length of follow-up and
number of study withdrawals.
• Participants: number, mean age, mean risk score.
• Intervention: type of intervention, dose and schedule.
• Outcomes:
◦ We will extract data to allow for intention-to-treat
(ITT) analysis where possible.
◦ For dichotomous outcomes (e.g. number of lymph
nodes, complications or deaths), we will extract outcome rates to
estimate a risk ratio (RR).
◦ For continuous outcomes (e.g. quality of life (QoL)
measures and duration of treatment) we will extract means and
standard deviations (SD) to estimate a mean difference (MD).
◦ For time-to-event outcomes (e.g. overall survival) we
will extract the log of the hazard ratio (log(HR)) and its standard
error from trial reports. If these are not reported, we will attempt
to estimate the log (HR) and its standard error using Parmar’s
methods (Parmar 1998).
Assessment of risk of bias in included studies
For future versions of this review we will assess the risk of bias
in included studies using The Cochrane Collaboration’s tool (
Higgins 2011) and the following criteria:
1. selection bias: random sequence generation and allocation
concealment;
2. performance bias: blinding of participants and personnel
(patients and treatment providers);
3. detection bias: blinding of outcome assessment;
4. attrition bias: incomplete outcome data;
5. reporting bias: selective reporting of outcomes;
6. other possible sources of bias.
R E S U L T S
Description of studies
Results of the search
The original search identified 706 citations, of which we retrieved
43 for detailed examination. We subsequently excluded 40 of these
records and three NRSs (two case-control studies and one case
series) were included in the original review (Ghezzi 2007; Hua
2005; Tozzi 2004; Figure 1). For this updated review, we excluded
these NRSs but tabled their findings with other similar studies that
were identified by the updated search (see Differences between
protocol and review).
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Figure 1. Study flow diagram of original search 17 May 2007
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From the updated search we identified 1395 records (1140 after
de-duplication), 28 of which we screened for possible relevance.
Of these, 11 new studies were identified for classification (Chen
2010; Chi 2005; Colomer 2008; Ghezzi 2009; Lee 2011; Nezhat
2009; Park 2008a; Park 2008b; Park 2010; Park 2011; Wu 2010;
Figure 2). Park 2008b, Park 2010 and Park 2011 are extensions
of the same series.
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Figure 2. Study flow diagram of updated search 30 November 2011
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Included studies
There were no studies that met the inclusion criteria.
Excluded studies
Altogether we excluded 54 studies. None of these studies met the
inclusion criteria in Types of studies. We have summarised the
results of the relevant case series, case-control studies and retro-
spective cohort studies in three tables: Table 1, Table 2 and Table
3, respectively. None of the comparative NRSs reported adjusting
results for baseline characteristics and we considered all of them
to be at a high risk of selection bias and other bias (e.g. outcome
assessment bias).
Risk of bias in included studies
Not applicable.
Effects of interventions
There were no studies to include therefore no meta-analyses could
be performed. Table 2 and Table 3 present the available data from
the case-control and retrospective studies to date.
D I S C U S S I O N
Stage I ovarian cancer is a rare disease and the use of laparoscopy
for surgical staging thereof is a relatively new field of clinical study,
therefore data are scarce. Recent UK guidelines on the manage-
ment of ovarian cancer do not consider laparoscopy as an approach
to the surgical staging of early ovarian cancer (NICE 2011); how-
ever, the German Gynaecological Oncology Group (AGO) have
cautiously included the option of this procedure in their recent
guidelines, for selected patients and only when performed by ex-
pert laparoscopic oncology surgeons, pending further evidence
(Mettler 2009).
Summary of main results
We found no randomised controlled trials (RCTs) to include in
this review and from which to compare the risks and benefits of
laparoscopy with the conventional open approach. Existing non-
randomised evidence comparing these interventions is extremely
limited and is particularly at risk of selection bias. We considered
including case-control non-randomised studies (NRSs) in meta-
analyses, however sample sizes were small, none of these studies
reported performing statistical adjustments for baseline case mix
using multivariate analyses (e.g. age, final FIGO stage, grade, tu-
mour size, co-morbidity and adjuvant chemotherapy), the dura-
tion of follow-up varied widely, and the primary outcomes of this
review (OS and PFS) were not consistently reported.
Overall completeness and applicability of
evidence
Survival
According to Surveillance Epidemiology and End Results (SEER;
Kosary 2007), five-year OS rates for stage Ia, Ib and Ic ovarian
adenocarcinoma (excluding borderline tumours) are about 94%,
91% and 80% respectively. However, survival data relating to the
surgical approach (laparoscopy versus laparotomy) in the existing
literature are extremely limited: comparative studies of laparoscopy
versus laparotomy for early ovarian cancer to date include three
case-control studies (Table 2; Chi 2005; Ghezzi 2007; Hua 2005)
and five retrospective cohort studies (Table 3; Lee 2011; Park
2008a; Park 2008b; Park 2010; Park 2011), three of which are
expansions of the same case series (Park 2008b; Park 2010; Park
2011). Of these eight studies, six reported survival data but the
length of follow-up varied widely or was not reported. Lee 2011
reported higher PFS rates in the laparoscopy group (100% for
laparoscopy versus 91% for laparotomy) and did not report OS,
however median follow-up was much shorter in the laparoscopy
group compared with the laparotomy group (12 versus 25 months)
and mean tumour size was significantly larger in the laparotomy
group (P = 0.01). Park 2011 reported OS of 89% and 86% for
laparoscopy and laparotomy respectively and PFS rates of 78% in
each group, but did not report the duration of follow-up in each
group. Ghezzi 2007 reported 100% OS in both groups, however
the median duration of follow-up differed substantially between
the groups (16 months in the laparoscopy group compared with
60 months in the laparotomy group).
Two studies conducted in women with early ovarian cancer (Park
2008a; Wu 2010) have reported unfavourable survival outcomes
with laparoscopy. In Park 2008a (OS = 88% in the laparoscopy
group versus 100% in the laparotomy group; Table 3), one woman
who was diagnosed with FIGO stage Ia grade 1 ovarian cancer was
shown to have severely disseminated disease at seven months and
died of the disease 15 months later; the other woman had stage
Ia grade 2 ovarian cancer at laparoscopy and developed recurrence
at the vaginal stump. The extent of laparoscopy surgical staging
was considered sufficient in the latter case, the tumour was not
ruptured and retrieval bags were used. Wu 2010 reported data from
a cohort of women with stage 1 ovarian cancer treated between
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1984 and 2006 and found that those in whom the initial surgical
approach was laparoscopic had significantly worse PFS and OS
than those who underwent laparotomy (OS hazard ratio (HR) =
3.52), however, comprehensive staging was not the purpose of the
laparoscopy in most of these women, therefore these results are
difficult to interpret. In general, we consider the available survival
data to be of a very low quality, hence it is not possible draw any
conclusions regarding the relative effect of laparoscopic surgical
staging compared with laparotomy on ovarian cancer survival from
the existing literature.
Feasibility
Measures of the technical feasibility of laparoscopy have included
pelvic and para-aortic lymph node yields, the size of the omental
specimen, operating times and intra-operative tumour spillage. All
case-control and cohort studies identified have reported statisti-
cally similar yields of retroperitoneal lymph nodes between their
laparoscopy and laparotomy groups. Only two comparative stud-
ies (Chi 2005; Park 2008b) have reported mean omental specimen
volumes, which were not statistically significantly different. With
regard to operating times, some studies report significantly longer
times with laparoscopy (Chi 2005; Ghezzi 2007; Hua 2005; Lee
2011) whilst others have reported significantly shorter times with
laparoscopy (Park 2008b; Park 2010; Park 2011). These differ-
ences probably reflect differences in surgeons’ skills and laparo-
scopic techniques between investigator teams.
Rupture or spillage of ovarian tumours during surgery has been
reported to occur more frequently with laparoscopy than laparo-
tomy (Romagnolo 2006) and has been identified as a prognostic
indicator of disease-free survival (Vergote 2001). To date, six out
of eight NRSs have compared rates of tumour spillage between
laparoscopy and laparotomy groups (Hua 2005;Lee 2011; Park
2008a; Park 2008b; Park 2010; Park 2011). Five of these studies
reported no significant difference between the two groups, and
one study (Lee 2011) reported a statistically significantly higher
rate of spillage in the laparotomy group (0% versus 14.9%; P
= 0.037) which also had a significantly larger mean tumour size
compared with the laparoscopy group. The definitions of spillage
vary and the distinction between tumour rupture and puncture
is not detailed in most studies (Ghezzi 2009). To properly assess
these outcomes, technique and definitions need to be clearly de-
fined in future studies. However, these limited data suggest that
laparoscopy staging of early ovarian cancer is technically feasible
when performed by experienced laparoscopic gynaecology oncol-
ogy surgeons.
An inherent shortcoming of laparoscopy for surgical staging is
the inability to palpate lymph nodes and other peritoneal surfaces
(Colomer 2008; Park 2008a), however Chi 2010 argues that intra-
operative direct visualisation and evaluation of nodes by palpa-
tion is inherently subjective. In a recent prospective study, of 111
women with apparent early ovarian cancer who underwent com-
prehensive staging by laparotomy that included retroperitoneal
lymph node dissection (RLND), retroperitoneal nodal metastases
were present in 13.5% of the women (Ditto 2012), which sug-
gests that without RLND many women would be under-staged.
However, systematic RLND may be associated with significant
morbidity and is not a routine part of staging for early ovarian
cancer in the UK, where clinical guidelines currently recommend
retroperitoneal lymph node assessment with sampling of suspi-
cious nodes (NICE 2011). Therefore, where RLND is not rou-
tine, lymph node palpation may play a crucial role in the decision-
making process with regard to sampling. Another technically dif-
ficult part of the surgical staging procedure is the examination of
the diaphragmatic peritoneum behind the liver and spleen and the
dome of the liver (Park 2008a); this may be more difficult with
laparoscopy, although it has been argued that isolated metastases
to these areas are rare (Ghezzi 2009).
Safety
Surgical staging for ovarian cancer is a radical procedure that
may be associated with severe intra-operative vascular, nerve, lym-
phatic, bowel and urinary tract complications. Common postop-
erative complications include wound infection, ileus, febrile mor-
bidity and lymphoceles (Ghezzi 2007; Lee 2011; Park 2008a; Park
2008b). Three comparative studies in early ovarian cancer have
reported significantly fewer postoperative complications with la-
paroscopy compared with laparotomy (Hua 2005; Lee 2011; Park
2011). The following complications have been reported in the la-
paroscopy participants of studies in early ovarian cancer: umbili-
cal hernias (Lee 2011), retroperitoneal haematoma (Ghezzi 2007),
vascular injury (Colomer 2008; Ghezzi 2007; Park 2008b), lym-
phoceles (Lee 2011; Nezhat 2009), obturator nerve damage (Hua
2005), bowel injury or obstruction (Nezhat 2009; Park 2008a)
and ureter injury (Park 2008b). Estimated blood loss (EBL) in
all case-control (Table 2) and comparative cohort studies (Table
3) has been statistically significantly less than in the laparoscopy
groups compared with laparotomy groups, with the exception of
one study (Ghezzi 2007). In these studies, rates of blood trans-
fusion in laparoscopy groups ranged from 0% to 15%, whereas
transfusions were necessary in up to 30% (Park 2010) of women
who underwent laparotomy.
There have been several reports of the occurrence of abdominal
wall metastases following laparoscopy for ovarian cancer (Childers
1994; Gleeson 1993; Leminen 1999). However, in the studies
of laparoscopy in stage I ovarian cancer that have reported this
outcome, no port-site metastases had occurred by the time of
reporting in Chi 2005 (20 women), Park 2008a (17 women),
Park 2008b (19 women), Nezhat 2009 (36 women) and Lee
2011 (26 women). Port-site metastases may be technique-related
and limited mostly to patients with advanced disease (Chi 2005;
Nezhat 2009). In a study of laparoscopic cytoreductive surgery
for advanced ovarian cancer and in which no port-site metastases
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occurred, the authors attributed their results to a surgical technique
that employed endoscopic bags to retrieve intact specimens and
a layered closure of the trocar site (Nezhat 2010). Lee 2011 and
Chi 2005 have also reported employing this technique to prevent
port-site metastases.
Other outcomes
Lee 2011 evaluated the relative cost of laparoscopy compared with
open surgery in women with early ovarian cancer and found that
laparoscopy resulted in higher costs due to the cost of disposable
instrumentation and direct material/operating room costs, but the
cost of hospital stay was higher in the laparotomy group because
the stay was longer. Where bed costs are higher, this difference in
cost might be eliminated, however the median lengths of hospital
stay in the laparotomy groups in most of the studies reporting this
outcome seem excessive with a range of up to 14.5 days (Table 2;
Table 3). Literature on the quality of life for women undergoing
laparoscopy compared with laparotomy is scant, however Lee
2011 reported significantly lower postoperative pain scores in the
laparoscopy group.
Agreements and disagreements with other
studies or reviews
A meta-analysis of eight RCTs comparing laparoscopic surgical
staging with laparotomy for endometrial cancer has shown the
laparoscopic approach to be safe, with statistically significantly
fewer postoperative complications than laparotomy, and similar
rates of intra-operative complications (Zullo 2012). It is possible
that similar conclusions may, in time, be drawn about laparoscopy
and laparotomy for stage I ovarian cancer, however the evidence
for this is not currently in the literature.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to technological advancements in instrumentation and an
increase in laparoscopic surgical expertise, the role of laparoscopy
in gynaecological cancers is expanding, however there is still wide
regional variation in the laparoscopic skills and competence of gy-
naecological-oncology surgeons. We did not find any good evi-
dence to recommend laparoscopy for the routine management of
women with stage I ovarian cancer.
Implications for research
Survival data for patients with gynaecological malignancies man-
aged by laparoscopy are still lacking. A major barrier to conduct-
ing randomised controlled trials (RCTs) in early ovarian cancer is
the anticipated difficulty in recruiting sufficient numbers of par-
ticipants (Ghezzi 2009). Other difficulties include standardising
the quality of the surgery and the skill of the surgeons. Subse-
quent results from such trials may only be applicable to expert
laparoscopic oncology surgeons. However, we understand, from a
personal communication, that the Korean Gynecologic Oncology
Group (KGOG) is currently developing a protocol for a RCT com-
paring laparoscopy with laparotomy for early ovarian cancer. Two
recently reported Korean cohort studies (Lee 2011; Park 2011) re-
cruited 325 women between them within the same six-year period
(2004 to 2010), suggesting that a multicentre RCT is feasible. Par-
ticipating institutions should be subgrouped according to whether
retroperitoneal lymph node dissection or lymph node assessment
with sampling is performed routinely. Outcomes of RCTs should
include overall and progression-free survival, complications (intra-
operative and postoperative), the use of adjuvant chemotherapy,
patient satisfaction, quality of life and costs. It would be helpful
if costs are reported separately for the preoperative, intraoperative
and postoperative periods.
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ovarian cancer; metastatic disease was discovered in 8 of these women (see Table 1).
Childers 1996 A series of 138 cases of laparoscopy for suspicious ovarian masses (not surgical staging). Malignancies were
discovered in 19 women
Colomer 2008 A prospective case series of laparoscopic surgical staging of 20 women with apparent early ovarian cancer (18
EOCs and 2 dysgerminomas) (see Table 1)
Darai1998 A retrospective case series of 25 women with borderline ovarian tumours
de Poncheville 2001 Retrospective study of surgery without para-aortic lymphadenectomy in stage I ovarian cancer. Investigators
advocate surgery without lymphadenectomy for women with early ovarian cancer
Dottino 1999 Retrospective case series of 94 laparoscopic lymphadenectomies for gynaecological malignancies, including 14
women with ovarian cancer
Ghezzi 2007 A case-control study of 15 women who underwent laparoscopic staging for early ovarian cancer versus 19
historical controls who had open surgery (see Table 2)
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(Continued)
Ghezzi 2009 A case series of 26 women who underwent laparoscopic staging for early ovarian cancer (see Table 1)
Goff 2006 Narrative review
Hua 2005 A small, prospective, case-control study of 10 women who underwent laparoscopic staging for early ovarian
cancer versus 11 women who underwent laparotomy (see Table 2). No adjustments were made for baseline
case mix.
Kadar 1995 Included other cancers (endometrial, cervical, ovarian)
Klindermann 1995 A survey conducted on laparoscopy in Germany
Leblanc 2004 Cohort with other types of cancer (fallopian tube carcinoma) and in patients that were inadequately staged at
the time of initial surgery for invasive ovarian carcinoma
Leblanc 2006 Narrative review
Lee 2011 A retrospective cohort study of laparoscopy in 26 women with early ovarian cancer versus 87 women who
underwent open surgery (see Table 3). No adjustments were made for baseline case mix. Women in the
laparotomy group had significantly larger tumours and longer follow-up
Lécuru 2004 Retrospective study of 105 women who underwent surgery for stage I ovarian cancer. 14 underwent laparoscopy
only, 13 had a laparoscopy converted to laparotomy and 78 had a laparotomy. Comprehensive staging was
less frequent in the laparoscopy group
Maiman 1991 Members and candidate members of the Society of Gynecologic Oncologists responded to a survey concerning
the “laparoscopy management of ovarian neoplasm subsequently found be malignant”
Malik 1998 Unexpected ovarian tumours were discovered in 11/292 women who underwent laparoscopy to evaluate
adnexal masses
Maneo 2004 Criteria for exclusion: 62 patients had fertility-sparing after surgery
Manolitsas 2001 Narrative review
Mehra 2004 A prospective case series of 32 women with ovarian and other gynaecological cancers who underwent laparo-
scopic retroperitoneal para-aortic lymphadenectomy
Nezhat 1992 Series of cases
Nezhat 2009 A case series of 36 women with early ovarian cancer who underwent complete laparoscopic staging (see Table
1)
Nezhat 2010 A case series of women with advanced ovarian cancer who underwent complete laparoscopic staging
Park 2008a A retrospective cohort study of 17 versus 19 women with early ovarian cancer who underwent laparoscopic
staging and laparotomy respectively (see Table 3). No adjustments were made for baseline case mix.
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(Continued)
Park 2008b A retrospective cohort study of 19 versus 33 women with early ovarian cancer who underwent laparoscopic
staging and laparotomy respectively (see Table 3)
Park 2010 An expansion of the earlier study (Park 2008b; see Table 3)
Park 2011 An expansion of Park 2008b and Park 2010 retrospective studies (see Table 3)
Parker 1990 This study only included women with benign ovarian cysts
Pomel 1995 A series of women with stage I ovarian carcinoma who underwent a laparoscopic procedure to complete their
staging
Querleu 2003 A retrospective study of laparoscopic restaging of 30 women with borderline ovarian tumours
Querleu 2006a Narrative review
Querleu 2006b Many types of tumours (cervical, vaginal, endometrial and ovarian carcinoma)
Reich 1990 A case report
Romagnolo 2006 A series of cases where laparoscopy was performed for suspected borderline ovarian tumours, and included
fertility-sparing procedures
Rouzier 2005 Narrative review
Spirtos 2005 A case series of laparoscopy for all stages of ovarian cancer and other types of cancers
Tozzi 2004 A case series of laparoscopic staging for early ovarian cancer (see Table 1)
Tozzi 2005 Narrative review
Tropé 2006 Narrative review
Vaisbuch 2005 Narrative review
Vergote 2003 Narrative review
Vinatier 1996 Narrative review
Volz 1997 Narrative review
Wenzl 1996 A questionnaire was sent to all 97 Departments of Gynaecology in Austria to determine the frequency of
discovering a malignant ovarian mass when laparoscopy is used to manage an adnexal mass
Wu 2010 A retrospective cohort study of laparoscopy versus laparotomy, however surgical staging was not always the
aim of the initial laparoscopy
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EOC = epithelial ovarian cancer
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S













PFS (%) OS (%)
Querleu 1994 8 - 8.6 - - - -
Pomel 1995 8 7.5 8.5 - - - -
Childers 1995 14 - - - - - -
Tozzi 2004 24 19.4 19.6 46 2 92 100
Leblanc 2004 42 14 20 54 3/34 ¹ 91 98
Colomer
2008
20 18 11.3 24.7 1 95 100
Ghezzi 2009 26 24.5 9.8 26.7 1 96 96
Nezhat 2009 36 14.8 12.2 55.9 ² 3 92 100
Chen 2010 43 16.6 6.5 24.7 3 93 -
Abbreviations: PFS = progression-free survival; OS = overall survival; n = number
¹Leblanc 2004 reported recurrences in confirmed stage I women only, i.e. excluding 8 women who were upstaged.
²Mean follow-up.
Table 2. Case-control studies of laparoscopic surgical staging versus open surgical staging of early ovarian cancer
Study
name
Hua 2005 Chi 2005 Ghezzi 2007
Period 2002-2004 2000-2003 2003-2006




LPS LPT P value LPS LPT P value LPS LPT P value
Number of
women
10 11 - 20 30 - 15 19 -
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Table 2. Case-control studies of laparoscopic surgical staging versus open surgical staging of early ovarian cancer (Continued)
Mean age 40 42 - 47.3 50.6 0.31 55 61 0.05
BMI (kg/
m²)
















25 ¹ 27 ¹ NS 12.3 14.7 NS 25.2 25.1 0.96
Para-aortic
nodes, n















2 (20%) ² 7 (72.7%) < 0.01 0 (0) 3 (10) - 2 (13.3%) 8 (42.1%) 0.13
Hospital
stay (days)
- - - 3.1 5.8 < 0.001 3 7 0.001
Final diag-
nosis
= stage I, n
(%)
- - - - - - 11 (73.3) 13 (68.4) -
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- - - - - - 0 4 (21) -
OS, n (%) - - - - - - 15 (100) 19 (100) -
Abbreviations: LPS = laparoscopy; LPT, laparotomy; BMI = body mass index; PFS = progression-free survival; OS = overall survival; n
= number; NA = not applicable; SD = standard deviation; NS = not specified.
¹Lymph nodes not specified as pelvic or para-aortic in origin.
²Right obturator nerve damaged and repaired in one patient.
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Table 3. Retrospective cohort studies of laparoscopic surgical staging versus open surgery for early ovarian cancer
Study
name





















































252 454 < 0.
001







0 (0) 2 (11) - 1 (5) 10
(30)
0.04 6 (15) 23
(30)














13.7 19.3 0.052 27.2 33.9 0.079 - - NS - - NS 23.5 22.8 0.867
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0 (0) 4 (21)
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3.8 2.0 < 0.
001
1.3 3.6 < 0.
001
1.7 3.6 < 0.
001













6.3 13.5 < 0.
001
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11.1 14.3 0.140 12.8 17.6 0.
049
12.8 13.9 < 0.
001
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0.731 - - -
Abbreviations: LPS = laparoscopy; LPT, laparotomy; BMI = body mass index; PFS = progression-free survival; OS = overall survival; n
= number; NA = not applicable; NS = not specified.
*These studies are expansions of the original data set (Park 2008b).
¹Wound infections, fever, ileus.
²Including one intra-operative great vessel injury repaired via a small abdominal incision.
³All these women were staged Ia/b compared with only five Ia/b and eight Ic cases in the LPT group.
Including 10 lymphoceles in the LPT group. Two umbilical hernias occurred in the LPS group.
One woman diagnosed as FIGO stage Ia grade 1 had severely disseminated disease 7 months postoperatively and died of the disease
15 months later. The other woman was stage Ia grade 2 at LPS and developed recurrence at the vaginal stump.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Ovarian Neoplasms explode all trees
#2 ovar* near/5 (cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan* or adenocarcinoma*)
#3 (#1 OR #2)
#4 MeSH descriptor Laparoscopy explode all trees
#5 laparoscop* or celioscop* or peritoneoscop* or (endoscop* near/5 abdom*)
#6 MeSH descriptor Laparotomy, this term only
#7 laparotom* or (abdom* near/5 (surg* or incision))
#8 (#4 OR #5 OR #6 OR #7)
#9 (#3 AND #8)
Appendix 2. MEDLINE search strategy
1 exp Ovarian Neoplasms/
2 (ovar* adj5 (cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan* or adenocarcinoma*)).mp.
3 1 or 2
4 exp laparoscopy/
5 (laparoscop* or celioscop* or peritoneoscop* or (endoscop* adj5 abdom*)).mp.
6 Laparotomy/
7 (laparotom* or (abdom* adj5 (surg* or incision))).mp.
8 4 or 5 or 6 or 7
9 3 and 8
10 randomized controlled trial.pt.
11 controlled clinical trial.pt.
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12 randomized.ab.
13 placebo.ab.
14 clinical trials as topic.sh.
15 randomly.ab.
16 trial.ti.
17 exp cohort studies/
18 exp case-control studies/
19 comparative study/
20 (cohort* or prospective* or retrospective* or control* or longitudinal or follow-up).mp.
21 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22 9 and 21
key: [mp = protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word,
subject heading word, unique identifier]
Appendix 3. EMBASE search strategy
1 exp ovary tumor/
2 (ovar* adj3 (cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan* or adenocarcinoma*)).ti,ab.
3 1 or 2
4 laparoscopy/
5 (laparoscop* or celioscop* or peritoneoscop* or (endoscop* adj3 abdom*)).ti,ab.
6 laparotomy/
7 (laparotom* or (abdom* adj3 (surg* or incision))).ti,ab.
8 4 or 5 or 6 or 7
9 exp controlled clinical trial/
10 cohort analysis/
11 exp case control study/
12 exp comparative study/
13 (randomized or randomly or trial* or cohort* or prospective* or retrospective* or control* or longitudinal or follow-up).ti,ab.
14 9 or 10 or 11 or 12 or 13
15 3 and 8 and 14
key: [mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword]
Appendix 4. LILACS search strategy
(MH:“ovarian neoplasms” or (ovar$ and (cancer$ or tumor$ or tumour$ or tumour$ or neoplas$ or carcinoma$ or malignan$ or
adenocarcinom$))) and (MH:“laparoscopy” or laparoscop$ or MH:“laparotomy” or laparotom$)
F E E D B A C K
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Definition of studies, 7 June 2015
Summary
Name: Alexander Melamed
Comment: The term “prospective case-control” is used in this study is confusing. Case-control studies by definition are retrospective.
A case-control study is one where patients with and without an outcome of interest are identified, and the presence or absence of a
putative causal exposure is investigated among these “cases” and “controls.” Perhaps what the authors of this study are referring to is
what would conventionally be called a cohort study. For a useful discussion of the confusion in regarding the terminology please see
Marshall T. What is a case-control study? International Journal of Epidemiology 2004;33:612-617.
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
The authors would like to thank Dr Melamed for taking the time to write, and we accept his suggestion. We have amended the term
prospective case-control to prospective cohort studies throughout the review.
Contributors
Theresa A Lawrie on behalf of the author team.
W H A T ’ S N E W
Last assessed as up-to-date: 23 November 2012.
Date Event Description
16 June 2015 Feedback has been incorporated Feedback received and responded too.
1 April 2015 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 4, 2008
Date Event Description
11 February 2015 Amended Contact details updated.
27 March 2014 Amended Contact details updated.
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(Continued)
20 December 2012 Amended Authorship order amended
12 September 2012 New citation required but conclusions have not
changed
Eleven newly identified studies excluded, no studies
included. Conclusions unchanged
30 November 2011 New search has been performed Search updated.
9 November 2010 Amended Author contact details amended.
14 May 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Lidia Medieros (LM), Daniela Rosa (DR), Mary Bozetti (MB), Maria Ines Rosa (MR), Alice Zelmanowicz (AZ) and Airton Stein (AS)
contributed to the writing of the protocol and the original review. LM, DR, MR, MB and Maria Edelweiss sifted the searches, selected
studies and extracted data for the original review (which included NRSs). Anaelena Ethur (AE) and Roselaine Zanini (RZ) contributed
to the protocol and methods section. Tess Lawrie (TL) sifted the updated search and wrote the first draft of the updated review. All
authors approved the final version.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
This review received methodological, statistical and editorial support as part of the 10/4001/12 NIHR Cochrane Programme Grant
Scheme: Optimising care, diagnosis and treatment pathways to ensure cost effectiveness and best practice in gynaecological cancer:
improving evidence for the NHS.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
For the original review (Medeiros 2008), we included NRSs and evaluated the quality of three studies (Ghezzi 2007; Hua 2005; Tozzi
2004) according to the STROBE and NOS tools. For the updated review, these studies were excluded, but we tabulated and discussed
the data with other NRSs.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Laparoscopy; ∗Laparotomy; Early Detection of Cancer [∗methods]; Neoplasm Staging; Ovarian Neoplasms [pathology; ∗surgery]
MeSH check words
Female; Humans
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